A decalogue of Molecular Tumor Board (MTB) recommendations from the CAN.HEAL Consortium

作者：Gennaro Ciliberto, Ruggero D. Maria, Patrizio Giacomini, Valentina Trapani, Martina Betti, Gabriele Bucci, Simonetta Buglioni, Lucia D’Auria, Roberta De Angelis, Arcangela De Nicolo, Célia Dupain, Nancy Frederickx, Maurizio Genuardi, Stefano Indraccolo, Monika Kolanowska, Luca Mazzarella, Frédérique Nowak, Matteo Pallocca, Jeanesse Scerri, Alessandro Sgambato, Tomasz Stokłosa, Marc Van den Bulcke, Els Van Valckenborgh, Nikolas C. C. von Bubnoff, Massimo Zeuli, Maud Kamal, Christophe Le Tourneau · 发表于：European Journal of Cancer · 年份：2025 · DOI：10.1016/j.ejca.2025.115433 · 被引用次数：7 · 研究领域：Cancer Genomics and Diagnostics、Lung Cancer Treatments and Mutations、Statistical Methods in Clinical Trials

INTRODUCTION: The CAN.HEAL consortium, comprising 47 cancer centers and academic institutions across 17 EU countries, has developed a set of recommendations for Molecular Tumor Boards (MTBs) to address the lack of standardized guidelines in personalized cancer medicine. METHODS: Over the past 2 years, through extensive collaboration and seven dedicated online meetings, CAN.HEAL experts developed consensus-based recommendations across 10 critical domains. RESULTS: The consortium agreed that MTBs' primary role is to perform molecular and clinical assessments for patients requiring care beyond standard treatment. Core MTB composition should include medical oncologists, molecular biologists, pathologists, and bioinformaticians. Patient eligibility criteria should prioritize performance status, with flexibility for rare cases. Shared informed consent is crucial for sample collection, data use, and research. A two-tiered IT workflow, with minimal and maximal datasets, is recommended, along with a comprehensive decision support tool. These recommendations focus on genomic testing, acknowledging diversity of NGS assays and proposing general guidelines. MTB reports should be concise, with technical details provided in the molecular diagnostic report. Innovative approaches like the Drug Rediscovery Protocol support access to off-label therapies. Harmonized training for MTB members is essential to bridging knowledge gaps in this evolving field. Indicators are needed to assess MTB effect...